NY-HOTWIRE
2.2.2021 16:05:12 CET | Business Wire | Press release
Hotwire, the global technology communications consultancy, today announced it will commit up to $1 million in services to support tech and tech-enabled organizations led by or supporting minority communities. The Program is part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to amplify people and organizations creating meaningful and sustainable change in the world through technology innovation.
“We started the Hotwire Ignite Possibility Program to direct more of our resources to organizations that align with our diversity, equity, and inclusion goals,” said Barbara Bates, CEO. “We have been providing pro bono services to impactful organizations for years, but now, with the Hotwire Ignite Possibility Program, we can do more to advance social justice through our services.”
Any tech or tech-enabled organization—for-profit, non-profit, education, or government—that is either minority-led or providing a product or service benefitting minority communities in a country with a Hotwire office may qualify. Hotwire will work with local community tech leaders addressing inequalities in business and tech to reach organizations who can benefit from brand, marketing or PR pro bono services.
“Having recently had the honor of being named Global Technology Agency of the Year by PRovoke Media, we have a responsibility to lead by example and address the inequality of resources for tech organizations,” noted Bates. “The Hotwire Ignite Possibility Program is one way we can do that,” she added.
Hotwire’s DEI strategy launched in early 2020 and includes specific commitments and a phased rollout schedule. Starting with internal operations and employee engagement initiatives aimed at building a diverse employee population and creating an inclusive environment where differences are celebrated, the firm is now extending the focus externally with the Hotwire Ignite Possibility Program. Hotwire has also signed the Diversity Action Alliance commitment, joining other PR and communications leaders to accelerate progress in the achievement of meaningful and tangible results in diversity, equity and inclusion across our profession.
By earmarking up to $1 million in services to organizations that meet the selection criteria, Hotwire is increasing the amount of support they provide to tech organizations in need of brand, marketing, and public relations expertise that otherwise may not have had access to these resources. The end goal of the Program is to help more tech and tech-enabled organizations that are advancing diversity, equity, and inclusion through technology innovation scale and succeed in today’s competitive tech sector.
Applications are now open for organizations in the US , UK and Germany until March 15th , 2021. An announcement of selected organizations in those countries will be made in April 2021. Applications for Australia open later in 2021 and Hotwire may reopen applications in other regions throughout the year. Follow us on Twitter and LinkedIn to get updates. Have questions? Email HIPP@hotwireglobal.com
About Hotwire
Hotwire is the global technology communications consultancy. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation.
About Enero
The Enero Group limited, a boutique network of marketing and communication businesses, is listed on the Australian Securities Exchange (asx:EGG). The group includes advertising agency BMF, PR agencies CPR, Frank and Hotwire, digital agency Orchard, research consultancies The Leading Edge and The Digital Edge, and programmatic marketing specialist OB media. For more information, please visit www.enero.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005795/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom